<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-12T11:18:06+08:00</updated>
  <subtitle>世事洞明皆学问，人情练达即文章</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>2021年全球畅销药TOP 10预测</title>
    <updated>2020-12-12T09:37:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/7jb6EqwXrjWy_3mTOPEdOA</id>
    <link href="https://mp.weixin.qq.com/s/7jb6EqwXrjWy_3mTOPEdOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新课表 | 亦弘商学院2021年主要课程目录正式发布</title>
    <updated>2020-12-12T09:37:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/lfk3hXJ6C24yXkucAfjltg</id>
    <link href="https://mp.weixin.qq.com/s/lfk3hXJ6C24yXkucAfjltg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药魔方招聘： HEOR Senior Manager, Associate Director, Director</title>
    <updated>2020-12-12T09:37:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/qZMtuzjlZ8fOwjhClc1VLw</id>
    <link href="https://mp.weixin.qq.com/s/qZMtuzjlZ8fOwjhClc1VLw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>吉利德14.5亿欧元收购全球首个丁肝新药</title>
    <updated>2020-12-11T07:38:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/bKYf6YcTUuseqxELfEnU8Q</id>
    <link href="https://mp.weixin.qq.com/s/bKYf6YcTUuseqxELfEnU8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首款皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药</title>
    <updated>2020-12-11T07:38:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/AYZAVUS1I41kVW6Qmk-s8Q</id>
    <link href="https://mp.weixin.qq.com/s/AYZAVUS1I41kVW6Qmk-s8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>11月肺癌月报 | 重磅研究、高分综述、新开试验，一文洞悉最新进展！</title>
    <updated>2020-12-11T07:38:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/LtLU_wq08Zn5rQlZZpsCow</id>
    <link href="https://mp.weixin.qq.com/s/LtLU_wq08Zn5rQlZZpsCow" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药与Applied BioMath启动肿瘤领域系统药理学建模的战略合作</title>
    <updated>2020-12-11T07:38:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/xSmuUbpNhzioOqm_YFrlPA</id>
    <link href="https://mp.weixin.qq.com/s/xSmuUbpNhzioOqm_YFrlPA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>制药巨头扎堆，外泌体赛道火热</title>
    <updated>2020-12-10T07:42:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/dEgWJUDjA4bfAMWYvnvkEQ</id>
    <link href="https://mp.weixin.qq.com/s/dEgWJUDjA4bfAMWYvnvkEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>开拓药业ALK抗体+Opdivo二线治疗晚期肝癌数据亮眼：客观缓解率达40%</title>
    <updated>2020-12-10T07:42:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/hMKXqSjNuHZy-06fEWrdAQ</id>
    <link href="https://mp.weixin.qq.com/s/hMKXqSjNuHZy-06fEWrdAQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日，和铂医药在港交所IPO上市</title>
    <updated>2020-12-10T07:42:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/AbNtFyxqauYsyMxMLF6giA</id>
    <link href="https://mp.weixin.qq.com/s/AbNtFyxqauYsyMxMLF6giA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药魔方招聘：医学数据经理</title>
    <updated>2020-12-10T07:42:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/WVo9pi1WRhj3PMTQLFU6Sg</id>
    <link href="https://mp.weixin.qq.com/s/WVo9pi1WRhj3PMTQLFU6Sg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗氏CD20×CD3双抗一线治疗DLBCL，完全缓解率79%</title>
    <updated>2020-12-09T08:39:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/I1KyiC8FJM4kc6kAf_ZGgw</id>
    <link href="https://mp.weixin.qq.com/s/I1KyiC8FJM4kc6kAf_ZGgw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和黄医药于上海张江举行创新药生产基地开工仪式</title>
    <updated>2020-12-09T08:39:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/wAcPicIpzTkygWFS8-51Mg</id>
    <link href="https://mp.weixin.qq.com/s/wAcPicIpzTkygWFS8-51Mg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>东曜药业公布ADC药物TAA013 I期研究结果</title>
    <updated>2020-12-09T08:39:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/By3zfNWYafpt6QAG7BOmyw</id>
    <link href="https://mp.weixin.qq.com/s/By3zfNWYafpt6QAG7BOmyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>凌腾医药宣布于10月6日完成卡妥索胃癌全球III期临床研究第一阶段首例患者给药</title>
    <updated>2020-12-09T08:39:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/_2kclkG5FHDfVUk5NF3tlQ</id>
    <link href="https://mp.weixin.qq.com/s/_2kclkG5FHDfVUk5NF3tlQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>10年上市3款单抗生物药，复宏汉霖进入新征程</title>
    <updated>2020-12-08T07:41:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/CK16LIHlhUIuuGVaD6FK1w</id>
    <link href="https://mp.weixin.qq.com/s/CK16LIHlhUIuuGVaD6FK1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Science子刊揭秘：抑制肿瘤复发的秘密武器——β受体阻滞剂</title>
    <updated>2020-12-08T07:41:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/qDp8blrxFU7DYcWbBB7uBw</id>
    <link href="https://mp.weixin.qq.com/s/qDp8blrxFU7DYcWbBB7uBw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>锐明新药完成数千万元A轮融资！加速推动wAMD项目申报和后续管线产品开发</title>
    <updated>2020-12-08T07:41:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/DW-uW0UX1-lEi8urbBnbNg</id>
    <link href="https://mp.weixin.qq.com/s/DW-uW0UX1-lEi8urbBnbNg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药宣布ATG-010与R-GDP联合用于治疗复发难治性弥漫性大B细胞淋巴瘤的全球多中心2/3期临床试验申请获中国药监局受理</title>
    <updated>2020-12-08T07:41:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/wYSHeR6Ebl61jBs7UWZ7Ig</id>
    <link href="https://mp.weixin.qq.com/s/wYSHeR6Ebl61jBs7UWZ7Ig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2020ASH】亚盛医药公布抗耐药白血病新药HQP1351（奥瑞巴替尼）关键性注册II 期研究的积极数据</title>
    <updated>2020-12-08T07:41:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/H1uHuNngo7bNuctUp-34gg</id>
    <link href="https://mp.weixin.qq.com/s/H1uHuNngo7bNuctUp-34gg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>